| Title |
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
|
|---|---|
| Published in |
Clinical Cancer Research, December 2021
|
| DOI | 10.1158/1078-0432.ccr-21-3032 |
| Pubmed ID | |
| Authors |
Yen-Shen Lu, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Fatima Cardoso, Nadia Harbeck, Sara Hurvitz, Louis Chow, Joohyuk Sohn, Keun Seok Lee, Saul Campos-Gomez, Rafael Villanueva Vazquez, Kyung Hae Jung, K. Govind Babu, Paul Wheatley-Price, Michelino De Laurentiis, Young-Hyuck Im, Sherko Kuemmel, Nagi El-Saghir, Ruth O'Regan, Claudia Gasch, Nadia Solovieff, Craig Wang, Yongyu Wang, Arunava Chakravartty, Yan Ji, Debu Tripathy |
X Demographics
The data shown below were collected from the profiles of 54 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 8 | 15% |
| Italy | 4 | 7% |
| Spain | 4 | 7% |
| United Kingdom | 3 | 6% |
| Canada | 3 | 6% |
| Colombia | 2 | 4% |
| Georgia | 1 | 2% |
| Mexico | 1 | 2% |
| Peru | 1 | 2% |
| Other | 4 | 7% |
| Unknown | 23 | 43% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 28 | 52% |
| Practitioners (doctors, other healthcare professionals) | 14 | 26% |
| Scientists | 10 | 19% |
| Science communicators (journalists, bloggers, editors) | 2 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 113 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 113 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 11 | 10% |
| Researcher | 10 | 9% |
| Student > Doctoral Student | 10 | 9% |
| Other | 9 | 8% |
| Student > Master | 7 | 6% |
| Other | 16 | 14% |
| Unknown | 50 | 44% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 41 | 36% |
| Biochemistry, Genetics and Molecular Biology | 7 | 6% |
| Unspecified | 3 | 3% |
| Business, Management and Accounting | 3 | 3% |
| Nursing and Health Professions | 2 | 2% |
| Other | 7 | 6% |
| Unknown | 50 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 64. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 February 2024.
All research outputs
#663,001
of 25,306,238 outputs
Outputs from Clinical Cancer Research
#398
of 13,212 outputs
Outputs of similar age
#16,690
of 517,003 outputs
Outputs of similar age from Clinical Cancer Research
#12
of 192 outputs
Altmetric has tracked 25,306,238 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,212 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.7. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 517,003 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 192 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.